2026 Interim report
Filed with HKEX · Stock code 2348 · · 74 pages · English and Chinese
Contents f} Corporate Information 公司資料 Group Structure 本集團架構圖 Financial Highlights 財務摘要 Management Discussion and Analysis 管理層討論與分析 Other Information 其他資料 Condensed Consolidated Statement of Profit or Loss 簡明綜合損益表 2 4 5 6 21 29 Condensed Consolidated Statement of Comprehensive Income 30篇明综合全面收关表 Condensed Consolidated Statement of Financial Position簡明綜合財務狀況表 31 Condensed Consolidated Statement of
Dawnrays Pharmaceutical Holdings Ltd. on 6ix
Earlier from Dawnrays Pharmaceutical
- Discloseable transaction - investment in a limited partnership
- Dawnrays Pharmaceutical Holdings: Proposals for general mandates to issue and repurchase shares; re-election of directors and notice of annual general meeting
- Next Day Disclosure Return
- Dawnrays Pharmaceutical Holdings: Supplemental announcement in relation to 2019 annual report
- Discloseable transaction-construction agreements
Later from Dawnrays Pharmaceutical
- Notification letter and reply form to registered shareholders - notice of publication of 2026 interim report
- Notification letter and request form to non-registered holder - notice of publication of 2026 interim report
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- (Revised) Next Day Disclosure Return
Follow Dawnrays Pharmaceutical into a list and get an email when it puts out news.
Follow Dawnrays Pharmaceutical